Zeenat Safdar MD MS, FACP, FCCP, ATSF

Internal Medicine•Houston, TX

Critical Care Medicine, Pulmonology

Professor of Medicine, Houston Methodist Hospital, Weill Cornell College of Medicine

Join to View Full Profile

6445 Main StreetOPC 22Houston, TX 77030
Phone+1 713-441-7182
Fax+1 713-796-1701

Summary

Director, Pulmonary Hypertension Care Center.
Director, Pulmonary Fibrosis Center Director, Houston Methodist Lung Center

Education & Training

Baylor college of medicineMS, Maters in Clinical Investigation, 2008 - 2015
New York-Presbyterian HospitalPost-Doctoral Fellowship, 2001 - 2005
Icahn School of Medicine at Mount Sinai/Morningside/WestFellowship, Pulmonary Disease and Critical Care Medicine, 1998 - 2003
Icahn School of Medicine at Mount Sinai/Morningside/WestFellowship, Pulmonary Disease and Critical Care Medicine, 1998 - 2001
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1995 - 1998
Eastern Virginia Medical SchoolInternship, Preliminary Year, 1994 - 1995
Sind Medical CollegeClass of 1991

Certifications & Licensure

TX State Medical License 2006 - 2025
NY State Medical License 1998 - 2010
NJ State Medical License 2003 - 2005
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease
Baylor college of medicineMaster of Clinical Sciences

Awards, Honors, & Recognition

Educational Leadership Fulbright & Jaworki Award, 2012
Teaching and Evaluation Fulbright & Jaworski Award, 2011
Academy of Distinguished Educators Baylor College of Medicine, 2011
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Join now to see all

Clinical Trials

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPLETED
PHASE4
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial Start of enrollment: 2010 Mar 01
Completed
Phase 3
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension Start of enrollment: 2011 Jul 01
Unknown status
Phase 4
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST Start of enrollment: 2016 Oct 04
Terminated
Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Start of enrollment: 2018 Aug 30
Recruiting
Phase 3
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RECRUITING
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) Start of enrollment: 2021 May 12
RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Clinical impact of pulmonary arterial hypertension on SARS-CoV-2 outcomes: U.S. pre-vaccination analysis.
Omar Tamimi, Chidinma Ejikeme, Tariq Nisar, Deepa Gotur, Zeenat Safdar
Current Problems in Cardiology. 2024-08-01
Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension.
Tejaswini P Reddy, Roberto Barrios, Eric Bernicker, Wei Qian, Jenny Chang
Pulmonary Circulation. 2024-07-01
1 citations
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.
Nick H Kim, Kelly M Chin, Vallerie V McLaughlin, Hilary DuBrock, Ricardo Restrepo-Jaramillo
Pulmonary Therapy. 2024-03-01

Press Mentions

Deadly Vaping Illnesses Linked to THC ProductsSeptember 27th, 2019
8 Deaths, 530 Illnesses from Vaping: Here’s What to KnowSeptember 23rd, 2019
Houstonians’ Say Their Allergies Are Horrible, but Doctors Think They Know What’s to BlameOctober 15th, 2017
Join now to see all